首页>
外国专利>
DETERMINING THE INTERACTION POINT BETWEEN P21-WAF AND PCNA AND THEIR THERAPEUTIC USE
DETERMINING THE INTERACTION POINT BETWEEN P21-WAF AND PCNA AND THEIR THERAPEUTIC USE
展开▼
机译:确定P21-WAF和PCNA之间的相互作用点及其治疗用途
展开▼
页面导航
摘要
著录项
相似文献
摘要
Substances are disclosed which have the property of binding to PCNA, the substances comprising (i) a fragment of the p21WAF1 protein including residues 141 to 160 of the p21WAF1 amino acid sequence, or an active portion or derivative thereof; or (ii) functional mimetics of these protein fragments. In particular, the PCNA binding activity is shown to lie within the sequence motif OTSMTDFY, with the residues shown in bold being critical for PCNA binding, with those underlined being important. These substances are useful in the treatments of disorders in which PCNA is implicated, e.g. hyperproliferative disorders such as cancer and psoriasis, the substances binding to PCNA to inactivate it or functionally deplete its level. Also disclosed is the use of a yeast two hybrid screening technique for screening candidate peptides for binding to PCNA.
展开▼